Page 3 - ஹாஃப்மேன் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஹாஃப்மேன் குழு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஹாஃப்மேன் குழு Today - Breaking & Trending Today

F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)


(0)
If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU
ENSPRYNG is the only subcutaneous treatment option for NMOSD that can be administered at home every four weeks
Recommendation is based on results from the two pivotal Phase III
SAkuraStar
SAkuraSky
studies, in which ENSPRYNG demonstrated robust and sustained efficacy in reducing the risk of relapse and a
favourable
safety profile
NMOSD is a rare, lifelong and debilitating autoimmune disorder of the central nervous system that can cause blindness, muscle weakness and paralysis ....

United States , Nathalie Meetz , Jon Kaspar Bayard , Levi Garraway , Daniel Grotzky , Karl Mahler , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Loren Kalm , Lisa Tuomi , Patrick Barth , Karsten Kleine , European Medicines Agency , European Commission , Roche Group , Head Of Global Product Development , Committee For Medicinal Products Human Use , Roche Group Media Relations , Medicinal Products , Human Use , Chief Medical Officer , Global Product , ஒன்றுபட்டது மாநிலங்களில் , ஜான் காஸ்பர் வளைகுடா ,

Hoffmann Green Cement Technologies: Hoffmann Green Is Participating, Alongside GCC, in the Production of Low-carbon Concrete Components for Aizenay High School


Hoffmann Green Cement Technologies: Hoffmann Green Is Participating, Alongside GCC, in the Production of Low-carbon Concrete Components for Aizenay High School
Hoffmann Green or the
Company ), a pioneer in clinker-free low-carbon cement, announces the first pouring of concrete sheets manufactured with its H-UKR cement by GCC for the construction of a public establishment in Aizenay, Western France.
Launched in October 2020, the Aizenay high school site is currently under construction. Designed to accommodate up to 800 students, this project is part of a program to build four new schools in Vendée, Western France to meet an increase in the number of high school students. ....

Pays De La Loire , Pierre Laurent , Nicolas Merigeau , Thomas Grojean Quentin , Regulatory News , Green Cement Technologies , Western France , Hoffmann Green , Hoffmann Green Cement Technologies , Financial Officer , Quentin Mass , Along Side , செலுத்துகிறது டி லா லாய்ர் , பியர் பரிசு பெற்றவர் , ஒழுங்குமுறை செய்தி , பச்சை சிமென்ட் தொழில்நுட்பங்கள் , மேற்கு பிரான்ஸ் , ஹாஃப்மேன் பச்சை , ஹாஃப்மேன் பச்சை சிமென்ட் தொழில்நுட்பங்கள் , நிதி அதிகாரி , குவென்டின் நிறை , நீண்டது பக்க ,

F. Hoffmann-La Roche Ltd: Roche's Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)


F. Hoffmann-La Roche Ltd: Roche s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
Evrysdi increased survival and reduced need for permanent ventilation
Evrysdi has proven efficacy across adults, children and babies 2 months and older
Basel, 15 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support. The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation . Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalisations compared to the natural course of Type 1 S ....

United States , Nathalie Meetz , Levi Garraway , Daniel Grotzky , Jon Kaspar Bayard , Karl Mahler , Sabine Borngr , Basil Darras , Gerard Tobin , Bruno Eschli , Birgit Masjost , Lisa Tuomi , Loren Kalm , Patrick Barth , Karsten Kleine , Toddler Development , European Commission , Drug Administration , Head Of Global Product Development , Professor Of Neurology At Harvard Medical School , Toddler Development Third Edition , Muscular Atrophy Program At Boston Children Hospital , Roche Group , American Academy Of Neurology , Pharmaceuticals Industry , Roche Group Media Relations ,